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Abstract
Background: Walking ability is a priority for many children with cerebral palsy (CP) and their parents when
considering domains of importance regarding treatment interventions. Partial body-weight supported treadmill
training has become an established therapeutic treatment approach to address this demand. Further, new robotic
rehabilitation technologies have increasingly been implemented in the clinical setting to allow for longer training
sessions with increased step repetitions while maintaining a consistent movement pattern. But the current evidence
about its clinical effectiveness in pediatric rehabilitation is weak. The aim of this research project is therefore to
investigate the effectiveness of robot-assisted gait training on improvements of functional gait parameters in
children with cerebral palsy.
Methods/Design: Children aged 6 to 18 years with bilateral spastic cerebral palsy who are able to walk at least 14
m with or without walking aids will be recruited in two pediatric therapy centers in Switzerland. Within a pragmatic
cross-over design with randomized treatment sequences, they perform 5 weeks of robot-assisted gait training
(three times per week with a maximum of 45 min walking time each) or a 5-week period of standard treatment,
which is individually customized to the needs of the child and usually consists of 1–2 sessions of physiotherapy per
week and additional hippotherapy, circuit training as well as occupational therapy as necessary. Both interventions
take place in an outpatient setting. The percentage score of the dimension E of the Gross Motor Function Measure-
88 (GMFM-88) as primary outcome as well as the dimension D of the GMFM-88, 6-minute and 10-meter walking
tests as secondary outcomes are assessed before and at the end of each intervention period. Additionally, a 5-week
follow-up assessment is scheduled for the children who are assigned to the standard treatment first. Treatment
effects, period effects as well as follow-up effects are analyzed with paired analyses and independent test statistics
are used to assess carry-over effects.
Discussion: Although robot-assisted gait training has become an established treatment option to address gait
impairments, evidence for its effectiveness is vague. This pragmatic trial will provide important information on its
effects under clinical outpatient conditions.
Trial registration: ClinicalTrials.gov: NCT00887848. Registered 23 April 2009.
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trial
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Background
Mobility in general as well as the ability to walk is a
priority for many children with cerebral palsy (CP) and
their parents when considering domains of importance
regarding treatment interventions [1]. Parents of children
with CP value walking, especially ‘correct’ walking, as a
key component of their children’s present and future well-
being [2]. Children with poorer walking abilities report a
reduced physical well-being [3]. Accordingly, acquir-
ing, retaining or improving gait function in these
children is often a main goal of the families and the
rehabilitation team.
As training intensity, frequency, specificity and level of
repetition with variation play a crucial role in promoting
sensomotor learning in patients with disorders of the
central nervous system, partial body-weight supported
treadmill training (PBWSTT) has become an established
therapeutic treatment approach [4–6]. Although two or
even three therapists may be needed in severely affected
patients to support the movement of the legs and
stabilize the pelvis and the trunk, PBWSTT takes an
important role in gait rehabilitation of adult patients
with a diagnosis of stroke, incomplete spinal cord injury
(iSCI), Parkinson’s disease (PD) or multiple sclerosis
(MS) [7–11]. There is also an increasing body of evi-
dence that PBWSTT improves walking ability, speed and
endurance in children, with most evidence being available
for children with mild to moderate cerebral palsy [12–15].
To allow for longer training sessions with more repeti-
tions while maintaining a consistent movement pattern
and reducing the burden of the therapists, new robotic
rehabilitation technologies have emerged during the last
15 years and have increasingly been implemented in the
clinical setting [16]. With the addition of virtual reality
(VR) scenarios, especially game-based VR, this type of
training further offers the patients diversification, fun
and challenge [17]. One domain of rehabilitation robots
involves driven gait orthoses (DGO) for robot-assisted
gait training (RAGT), which have been originally devel-
oped for adults and subsequently adapted for children
[18–20]. One of these DGOs is the Lokomat (Hocoma
AG, Volketswil, Switzerland, Fig. 1), which, by using the
pediatric version, allows a training for children starting
at an age of approximately 4 years.
RAGT with the Lokomat appears to be effective in
improving walking abilities in adult patients with stroke
or iSCI [21–23]. A systematic review confirmed these
results and showed limited evidence in patients with
MS, traumatic brain injury (TBI) or PD [16].
In the last years, RAGT has also been tested and im-
plemented in the pediatric neurorehabilitation setting
and has been found to be a feasible and safe therapeutic
option [20, 24]. However, the current evidence about the
clinical effectiveness of RAGT in pediatric populations is
weak. Most published results derive from uncontrolled
single case studies or case series [20, 25–28] and the few
published controlled trials [29, 30] provide inconclusive
results so far.
The aim of this research project is therefore to in-
vestigate the effectiveness of RAGT on improvements
of functional gait parameters in ambulatory children
with cerebral palsy in a pragmatic, randomized cross-
over trial.
Our hypothesis is that a 5-week phase of RAGT on
the Lokomat in an outpatient setting is superior with
regard to the improvement in gait function measured
with the dimension E of the Gross Motor Function
Measure-88 (GMFM-88) compared to a 5-week phase of
standard treatment encompassing conventional physiother-
apy lessons in children with spastic CP within a cross-over
design with a randomized treatment sequence.
Methods/Design
The design of the study was developed in accordance
with the current (2013) version of the Declaration of
Helsinki [31] and the extensions of the CONSORT
(Consolidated Standards of Reporting Trials) statement
for nonpharmacologic treatment interventions [32] as
well as for pragmatic trials [33].
Written informed consent and assent is obtained from
all the legal guardians and the child by the PI prior to
participation.
Design and setting
This study is designed as a bicenter, single-blinded,
pragmatic, randomized cross-over trial. It is carried out
in the outpatient setting of the rehabilitation center of
the Children’s University Hospital Zurich in Affoltern
am Albis and the Pediatric Therapy Center of the Reha
Rheinfelden (Switzerland). Children are randomized to
two different pre-specified sequences of interventions.
The two interventions are RAGT (T) and usual care (C).
A child can be randomized to a T/C sequence (TC-group)
or to a C/T/C sequence (CTC-group).
The duration of study participation varies dependent
on group allocation (Fig. 2): Children allocated to the TC-
group start with a first assessment, followed by a 5-week
period of RAGT (T-sequence), a subsequent second
assessment, a 5-week period of usual care (C-sequence)
and a third assessment. Individual study participation will
accordingly last 11 weeks for children in the TC-group
with three assessment time points.
In contrast to that, children allocated to the CTC-
group start with an assessment followed by 5 weeks of
usual care (C-sequence) and a subsequent second assess-
ment. This is succeeded by a 5-week period of RAGT
(T-sequence), a third assessment, another 5-week period
of usual care (C-sequence) and a follow-up assessment.
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Thus, study participation for children assigned to the
CTC-group lasts 16 weeks. The rationale for the differ-
ences in study duration and number of assessments
between the study groups is that we want to reduce the
burden for the children and their families as much as
possible while still gaining information on the preservation
of a potential effect at follow-up.
Eligibility criteria
Children aged 6 to 18 years with the diagnosis of a bilat-
eral di- or quadriplegic spastic CP and a Gross Motor
Function Classification System (GMFCS) level II-IV,
who are able to walk at least 14 meters with or without
walking aids, are eligible for study participation. Al-
though we are aware that these criteria encompass a
wide range of different motor abilities and developmen-
tal states, we consider it important that our study
population represents the whole range we encounter in
clinical practice. Further, they have to be able to follow
instructions and communicate pain or discomfort.
Exclusion criteria are neurosurgery or orthopedic surgery
on the lower extremity or trunk within the last 6 months,
Fig. 1 Pediatric robot-assisted gait training with the Lokomat. The Lokomat automates gait therapy on a treadmill by two actuated leg orthoses,
which can be individually adapted to the patient’s legs and attached with three cuffs, while the patient is secured by means of a counter system
with a harness providing partial body-weight support
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having participated in another Lokomat training regime
within the previous 6 months as well as a change in
concomitant treatment within the last 4 weeks
before or during the study period. This holds true
for all contraindications outlined in the Lokomat
manufacturer’s manual, as for example severe con-
tractures (i.e. > 20° knee extension deficit, >40° hip
extension deficit), bone fractures, open skin lesions
or circulatory problems. Further criteria and their
clinical implementation are described in a recently
published paper by a Lokomat expert panel [34].
Recruitment
Patients are recruited by announcement in schools
for children with special needs, in pediatric clinics
and in outpatient pediatric physical therapy prac-
tices. Additionally, we will inform parents of children
who have previously trained on the Lokomat and
who fulfill the inclusion criteria about the study in a
letter. Information about the study is also made
available on the website of the two participating cen-
ters as well as of the association of Swiss pediatric
physiotherapists. Families interested in participating
can then take the initiative and contact one of the
two rehabilitation centers.
Randomization, allocation concealment, and blinding
Randomization into the two groups with different inter-
vention sequences is performed using a minimization
method with a random factor of 0.9, including the fac-
tors severity of impairment (GMFCS-level II or III/IV),
age (6–11 years or 11–18 years) and Botulinum Toxin
A-treatment (present or absent) in the preceding
6 months. Minimization facilitates balancing even small
groups in terms of selected patient factors at all stages of
a trial. To ensure that group allocation is concealed for
patients and their families as well as everyone who is
involved at any stage of the trial, the randomization list
is generated by a person not belonging to the study team
on www.randomizer.at and stored off site. Directly after
inclusion of the patient the principal investigator (PI)
seeks information about group allocation through a
phone call or an e-mail. As soon as a child is allo-
cated to one of the two groups, the assessments and
trainings are planned according to the assigned inter-
vention sequence, taking into account as much as
possible the families’ requests and the school schedule
of the child.
The rater of the primary outcome and parts of the
secondary outcomes is blinded as the performance of
the child in these tests is video recorded and scored by
means of these videos with the rater being unaware of
Fig. 2 Overview of the outcome measures and the measurement time points per group. Abbreviations: RAGT: Robot-assisted gait training;
GMFM-88: Gross Motor Function Measure-88; 10MWT: 10-m walking test; *on an optional basis
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the date the video has been recorded. The same applies
to the statistician.
Intervention
RAGT (T-sequence)
Protocols for PBWSTT as well as RAGT in children are
very heterogeneous so far. Session frequencies range
from 2 to 5 times per week, session durations vary with
most studies reporting 20 to 30 min of treadmill walking
per session, and length of treatment varies from 2 weeks
to 5 months [34]. As our training protocol prescribes
the Lokomat training on an outpatient basis, we con-
sider a session frequency of three times per week with a
maximum of 45 min of effective walking time on the
Lokomat as feasible and a treatment duration of 5 weeks
as clinically adequate.
Trained and experienced therapists, who are used to
working with children, perform the Lokomat trainings.
The trainings are executed following recently pub-
lished recommendations [34]. Virtual reality scenarios
and other available motivating strategies are used in
order to increase the child’s adherence to the training.
Body-weight support, gait speed as well as guidance
force of the Lokomat are individually adjusted accord-
ing to the child’s abilities and modified within training
sessions and during the course over time. To ensure
that uniform standards are applied in both centers, a
joint practical training session has been performed and
the clinical training standards have been discussed
beforehand.
Standard therapies can be continued during the inter-
vention period, but should not include specific walking
training and not be changed in frequency. Parents list
the type as well as the dosage of concomitant therapy in
a personal logbook.
Usual care (C-sequence)
Usual care normally comprises 1–2 sessions of physio-
therapy per week. Hippotherapy, circuit training as well
as occupational therapy can also be elements of standard
treatment. These therapies, which are individually cus-
tomized to the needs of the child, are often implemented
in the school setting. The content of the usual care treat-
ment does not specifically address gait training, but
rather consists of elements addressing range of motion,
tone reduction, balance, activities of daily living, etc.
Information about the type and dosage of all therapies is
documented in a personal logbook by the parents. As
the treatment in our study should represent usual care
in clinical practice, we refrained from increasing the
dosage for the usual care treatment to a comparable
level as for the RAGT intervention.
Descriptive parameters and measures describing the
interventions
An overview of all outcome measures and measurement
time points is provided in Fig. 2.
To make sure that the therapists from both centers
apply common standards, all performed measures have
been thoroughly discussed and trained within and
between the teams.
Descriptive and clinical data like diagnosis, walking
aids, undergone operations, age, height and weight are
recorded in order to describe the characteristics of the
included patients. A description and quantification of
the RAGT sessions is provided by various measures
including the percentage of body weight support, gait
speed, guidance force, distance walked and the number
and duration of training sessions.
Primary outcome measure
The primary outcome measure is the percentage score
of the dimension E (walking, running, jumping) of the
Gross Motor Function Measure-88 (GMFM-88). It
assesses the gross motor function with regard to walking
ability [35]. The GMFM is a well-validated measurement
tool for children with CP, which can be regarded as a
gold standard for the assessment of gross motor func-
tion in children with CP. The dimension E consists of 24
items, each of which is scored on a 4-point ordinal scale.
The children perform the test barefoot, or with shoes
and orthoses, if orthoses are used when walking indoors
in everyday life. The test is performed without walking
aids, regardless of the children’s GMFCS-level. A
GMFM-certified therapist instructs the children while
the test is simultaneously videotaped. These videos are
later scored by a blinded rater, who is also a GMFM-
certified therapist. The psychometric properties of the
total GMFM-88 are well explored in children with CP.
Nevertheless, information on single dimensions is rather
sparse. There is limited positive evidence for the respon-
siveness of dimension E, while evidence on reliability is
still unknown because of too little patients included in
the reliability studies [36]. A recently published study
showed that video rating is a reliable option for the
dimensions E as well as D with ICCs of 0.992 and 0.965
for the agreement of life and video scores [37].
Secondary outcome measures
GMFM dimension D
The percentage score of the dimension D (standing) of
the GMFM-88 to assess the gross motor function with
regard to standing ability. The 13 items are carried out
and video rated in the same way as described for the
dimension E. As for dimension E, there is evidence for
responsiveness of dimension D [35]. Reliability seems to
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be high, but sample sizes of these studies were rather
small to allow definite conclusions [35, 38].
Six-minute walking test
The 6-minute walking test (6MinWT) is performed on a
30-meter long corridor with poles at each end. The
instruction and encouragement of the child follows a
standardized test protocol and the covered distance is
noted to one meter [39]. Evidence for the test-retest reli-
ability of the 6MinWT is moderate; its responsiveness
has not been established in children with CP so far [36].
Ten-meter walking test
Gait speed is assessed with the 10-meter walking test
(10MWT), which is performed on a 14-meter long track
with the child using the walking aid usually used in daily
life. The time needed for the middle 10 meters is
measured with a stopwatch, allowing 2 meters for accel-
eration and deceleration each. The test is performed
twice without a break. For the evaluation of fast speed
(10MWTfast), the child is instructed to walk as fast as
possible but without running, from the first to the last
line. The faster out of two trials is used for further
analysis. For self-selected speed (10MWTss) the child is
instructed to walk in a normal, comfortable speed from
the first to the last line and the mean of two trials is
calculated. All gait tests are performed with orthoses
and walking aids usually used in daily life. Evidence for
test-retest reliability of the 10MWTfast is moderate in
children with CP [36]. To our knowledge, responsiveness
of the 10MWTfast as well as psychometric properties of
the 10MWTss has not yet been established in children.
Measures of body function
Regarding the child’s body function level, range of motion,
modified Ashworth scores, and muscle strength by means
of manual muscle testing are evaluated in flexion and
extension of the hip, knee and ankle joints [40, 41]. These
measures will be used for descriptive purposes only.
One complete assessment block takes maximally 120 min.
Additionally, children perform a 3-dimensional gait
analysis (3DGA) on an optional basis before and at the
end of the intervention period to capture spatio-
temporal and kinematic data of the lower body during
walking. The Helen Hayes marker set with 16 markers
for the lower body, seven infrared Vicon MX cameras
(Oxford Metrix Ltd., Oxford, UK) and two floor-mounted
force platforms (AMTI OR 6-7-2000, Advanced
Mechanical Technology Inc., Watertown, MA, USA)
are used for the 3DGA. The mean of six clean force plate
strikes for each foot and each parameter of interest is
calculated for further analysis to obtain a reliability level
of at least 0.9 for each evaluated discrete gait parameter
irrespective of the child’s GMFCS level [42].
Sample size and power calculation
A sample size calculation for a 2×2 cross-over design was
performed. It indicated a sample size of 30 to be sufficient
to detect a difference of 3.7%-points in the dimension E-
score of the GMFM-88 [43], assuming a standard devi-
ation of 6.8%-points [25], a power of 80% and a signifi-
cance level of 5%. The 3.7%-points represented the cut-off
value that best differentiated between great and not great
improvement in motor function in children with CP as
judged by their therapists [43]. This number has been
increased to 34 to allow for a predicted dropout rate of
about 10%.
Statistical analysis
All data are electronically filed by the PI using EpiData
software with double data entry and range checks for
data values (EpiData Association, Odense, Denmark).
The statistical analyses are carried out with SPSS24
(IBM Corporation, New York, USA) and datasets of all
study participants are analyzed on an intention-to-treat
basis. Descriptive parameters of the participants will be
presented. Treatment effects, period effects as well as
follow-up effects of the two different treatment interven-
tions are analyzed with paired t-tests or Wilcoxon
signed-rank tests for paired samples, with the treatment
effect being our primary end-point. Unpaired two-sample
t-tests or Wilcoxon rank sum tests for unpaired samples
are used to determine whether carry-over effects are
present [44]. Ninety-five percent confidence intervals
are presented with a two-tailed level of significance
set at p < 0.05. The applied analyses are schematically
listed in Fig. 3.
Subgroup analyses are performed according to impair-
ment level (GMFCS level II vs. GMFCS levels III and IV)
and treatment adherence (12 or more training sessions
completed vs. less than 12 training sessions), given
sufficient numbers within the subgroups.
Missing data will be handled with multiple imputation
procedures [45].
Discussion
RAGT was implemented in the clinical setting of the
two participating pediatric neurorehabilitation centers as
innovative therapeutic approach almost 10 years ago. It
has become an established treatment option in these
clinics to address gait impairments in the in- as well as
outpatient setting despite the fact that evidence for its
effectiveness is vague. As we want to determine the
effects of RAGT as it is applied in the clinical setting, we
designed this pragmatic trial. The pragmatic trial design
allows to evaluate the effects of an intervention under
the usual conditions in which it is applied, whereas
explanatory trials determine the effects of an interven-
tion under ideal circumstances [46]. Thorpe et al.
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defined a pragmatic-explanatory continuum, an instru-
ment to determine the extent to which a trial can be
viewed as pragmatic or explanatory [46]. Our trial
addresses most domains at the rather pragmatic end of
this continuum. We make concessions towards a more
explanatory approach in two domains: Regarding the
flexibility of the experimental design, we standardize
frequency, timing and duration of the RAGT interven-
tion and impose some restrictions regarding the co-in-
terventions. A further domain concerns the primary
outcome assessment: While we use the dimension E of
the GMFM-88, which is a standard outcome in our clinics
as well as for the assessment of gross motor functions in
children with CP, we deviate from a clear pragmatic
approach by videotaping the assessments and including an
additional follow-up assessment. We are confident that
the chosen trial design allows the evaluation of the effects
of RAGT as it is implemented in the daily routine of our
clinics, while keeping the additional burden for the partici-
pating children and their families as low as possible. This
is also the reason why we perform the follow-up assess-
ment only in one group. As participation in this trial still
requires a considerable amount of time, we expect some
difficulties in recruitment. The study is therefore carried
out in two centers, namely the only two centers in
Switzerland that offer a pediatric Lokomat training on a
regular basis so far. In addition, we designed the study as
a cross-over trial. The strength of this design is that each
child receives both treatments, but in a random order.
Thus, each patient can act as his or her own control
requiring only half the number of patients needed in a
parallel group design. As variation within a person is
usually less than between patients the treatment effect can
be estimated with higher precision despite smaller sample
sizes [44]. On the other hand, a disadvantage of the cross-
over design is the risk of possible carry-over effects, which
means that the effect of the treatment in the first period
has an effect that lasts into the second period. A carry-
over effect leads to an underestimation of the effect of the
treatment in the second period. By introducing a washout
period between the different treatment periods, this risk
could be reduced. Introducing a washout period would
lead to an additional assessment. In order to reduce the
load of the participants to a minimum we abstained from
a washout period being aware that this might influence
our results.
Although the 5-week follow-up period is rather
short, we opted for this time frame because of the
increasing risk of confounding factors that is accom-
panied by a long time interval due to growth, new
therapy approaches, illness, operations, increased
school load etc.
Trial status
August 2009 - November 2018.
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